Tags : Solid Cancers


Roche Signs an Agreement with Innovent to Develop Therapies for

Shots: Roche to receive upfront, development and commercial milestone payments plus royalties and retains option to license for each ex-China development and commercialization. Innovent to get non-exclusive access to certain technologies of Roche to discover and develop specific 2:1 T-cell bispecific Abs (TCB) and the universal CAR-T platform If Roche exercise the option, it will […]Read More


Roche and Immatics Collaborate to Evaluate IMA101 + Tecentriq (atezolizumab)

Shots: The companies enter into a clinical research collaboration for the evaluation of efficacy and safety of immunotherapy combining Roche’s Tecentriq (atezolizumab) with Immatics’ IMA101 in solid tumors In H2’19, companies plan for the onset of the trial based on ACTolog IMA101-101 study protocol at MD Anderson Cancer Center to kill cancer cells by blocking […]Read More